Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneTelomerase: The Devil InsideReactivation of telomerase in cancerCell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomenaCancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer.TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCRTERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder CancerUse of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer.Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-upNucleic acid-based biomarkers in body fluids of patients with urologic malignancies.Telomerase promoter mutations in cancer: an emerging molecular biomarker?Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Beyond the exome: the role of non-coding somatic mutations in cancer.Understanding TERT Promoter Mutations: A Common Path to Immortality.TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.Urothelial Bladder Cancer Urinary Biomarkers.Telomere-driven diseases and telomere-targeting therapies.Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.TERT Core Promotor Mutations in Early-Onset Bladder Cancer.Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.Liquid biopsies for bladder cancer.Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation.Analysis of Point Mutations in Clinical Samples of Urothelial Carcinoma.Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.Bladder cancer.Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.Frequency of TERT promoter mutations in primary tumors of the liver.
P2860
Q51951823-5A2A00E3-F30B-4AF7-AA33-E6B4873BE524Q52155313-CC2EE55C-EFED-46C6-A092-E86598C2F321Q54583653-0E6F4C71-ECD5-4DCD-B9A9-986DFE970920Q54603866-DCC94CA9-B765-4B1F-BB9B-90E40B2112E0Q54605662-11A00709-CE11-497A-895D-B00DC4C20E9AQ54605778-2E65E276-E8FC-4C67-AE09-62F0EEB8F616Q54605797-FB69666B-D305-4FF1-85E1-D269BE5F6FDFQ54605808-9732DC3E-093D-4C98-AC67-AA12B0B31F3DQ54605814-274D6714-5507-494F-9D85-20E586FFDEB7Q54605817-A236ED16-DA93-43E4-A93F-07A4592C00E4Q54605829-437693D8-AC8A-48D5-8FD2-1981CB35F7FEQ54795193-E8D6560E-0A43-44A6-8544-4EB3B32F09EEQ54796201-2A73D020-D98E-4A26-B3ED-6F1142B3AADDQ54796210-DAEB472F-911C-4D82-8F27-4C63CAC938BAQ54808396-0A82B5C4-5FD7-44DB-A668-282B4F3B5723Q54831450-8C91F86D-23E2-46E2-BF6E-DDE80F1FCB9FQ54882078-CAE99827-1D48-4219-8FE8-0E55FC075D99Q54896502-2C77A638-B7FF-4BF1-8C16-065654B9CCF8Q54896503-59F23305-27AC-4111-9151-2908D520DF42Q54898490-6DA1A973-AC14-4CEF-B306-D283B63A79BCQ54899011-8C87F365-801A-428A-8FE0-BFC7B2F640DDQ54899036-76D553E4-4192-4072-A7E2-D18E9B1A8D96Q54900670-EC709C84-3376-4A3D-B385-EA53286C68CBQ54903247-99F32310-7B5D-4C41-AC65-53B378E567B3Q54903248-7A8A1000-AEFC-48EF-9691-72CD54AE8D45Q54903249-90C5BAF4-4BA2-4EB4-A79A-BF31596D97B0Q54903250-859A7500-AF6C-439E-A00C-E4209E790DD2Q54903251-2D9BBD3E-AC08-4C36-AB0F-FC3B899E603AQ54903252-782E1181-ABA0-4AD1-9D7C-2AC7A141750EQ54903253-ED2C156F-B81D-4B36-B0F1-8827D7556DFDQ54903254-9D32C528-F669-4E2B-8282-F6594EABE971Q54903255-4B415611-E11B-4285-AEF5-1602FF759BE4Q54905462-D84FD203-D697-418B-B332-856696B1BAC9Q54951347-BBD674EB-711E-4E57-9E2D-C008F47C2375Q54951351-B7E62128-703D-4AB7-8C4C-D70FAC1641D2Q54952320-DBA31A23-9C93-416A-9A23-4278E703523DQ54952678-BAB3516C-45B5-43A2-B1AF-4212DAFDB697Q54971090-A4BF8FCC-4FC8-4BF4-A0CA-A36BBE704692Q54971204-CB015416-C750-4054-ABBC-3C5CBA6CED79Q54971454-3BBAC566-5464-4E5D-A1A2-A23C311B3BD4
P1343
Q26738705-CA6F396D-BD51-4077-ADA5-055B25F157B6Q26739925-5E3E4948-4CF6-42C7-B6ED-0C9132FBB481Q26739948-008DC45F-206D-4A15-A7CD-D12C32991317Q26769014-83AEFAA4-D71D-412C-9378-9397C7960CBAQ26860953-E7A5AC73-3520-417D-A14D-3D8736FE7ADFQ30459452-7E89F4B1-E6A1-4783-A3D2-46AA29D03961Q33618591-27DA592C-7479-4161-85B0-AD975A6B607CQ33688439-C5FE5898-0511-4EC0-B0CB-56BCB8E7A234Q34150095-B5F636E9-1946-406E-9898-CAEF691B3E25Q35068013-2A8A41A3-D837-46B6-8B41-29712DAC0304Q35151119-38B9820C-4E34-4293-A691-241BE3322619Q35638497-DD169558-BB68-4FCE-B7B2-E651BDE2CB4FQ35743608-0EFCBEC4-FC59-4DF1-B1D1-187588A7AE4DQ35930911-956BEEB9-9AA6-4D7C-8F7B-E9E3B769E02FQ37566478-D6F44495-3FA2-47C8-A1BA-F746EEED5D22Q37649062-29BD69D9-00E4-453C-BB9F-997D1F3A614BQ37687183-913756B7-4127-4A2D-9574-BE0B47D7FE6DQ38216129-0FEE20DE-D859-400A-8AA0-48AD8F0E42BFQ38232447-7C7D2995-1FF1-4913-BCB7-E0EA77598635Q38297729-C71F7EE4-873F-4521-8C70-E9205448ACDBQ38645015-43609B0F-CD35-4AD5-AFB5-03EDDF6CE7E5Q38760235-AFB63B0A-B76E-4840-BB11-4E72DE953038Q38774845-04D6C3A6-C403-404C-AEB7-5E55552F720DQ38862963-42E10DE1-64F4-45A3-B075-81C82D5C13BEQ38967481-A462A660-10EE-42A8-95EC-B075AB543A2FQ39158816-035F199E-34DC-4C92-963F-ADA94786EB7BQ39352697-5AA4B097-EFFC-4EBE-B16B-2F553D02AE95Q39676067-BCFBD025-EAA1-4C0D-9B2B-BD3E5F2D25E7Q40145261-751101CA-1183-4D5D-80BB-8BDEFB28D957Q40199208-25EDCC51-C715-4F22-BC2C-8E579C6A5C72Q41449866-AFE95418-558B-439E-A2E4-9FD498695C2CQ42353512-E1DA20CC-09DB-432E-8E30-DD1A71901A75Q46754264-FC5BC1DA-6BB5-446F-AF41-A1E0E53EDE04Q50072573-1E270C16-5138-4187-98D7-E087CD9FCB67Q50182692-3A83C834-D42A-404F-B124-421797294D2EQ52646970-124DA379-F936-4634-BEAE-9E1D77C791FDQ52727349-1086DCC2-94A2-4A79-BBE0-A17D649BCC18Q52810295-603694FE-497E-46DE-A542-C8203DA81A60Q52956152-04D945CC-777A-46F0-9CFC-62F7D906B756Q54190292-61DDC76B-E8A1-4570-8FE5-127D1122D422
P2860
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Comprehensive mutation analysi ...... of mutations in voided urine.
@en
Comprehensive mutation analysi ...... of mutations in voided urine.
@en-gb
Comprehensive mutation analysi ...... of mutations in voided urine.
@nl
type
label
Comprehensive mutation analysi ...... of mutations in voided urine.
@en
Comprehensive mutation analysi ...... of mutations in voided urine.
@en-gb
Comprehensive mutation analysi ...... of mutations in voided urine.
@nl
prefLabel
Comprehensive mutation analysi ...... of mutations in voided urine.
@en
Comprehensive mutation analysi ...... of mutations in voided urine.
@en-gb
Comprehensive mutation analysi ...... of mutations in voided urine.
@nl
P4510
P1433
P1476
Comprehensive mutation analysi ...... of mutations in voided urine.
@en
P2093
Carolyn D Hurst
Fiona M Platt
P304
P356
10.1016/J.EURURO.2013.08.057
P407
P577
2013-09-03T00:00:00Z